These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 31734401

  • 1. Systemic sclerosis induced by CNS stimulants for ADHD: A case series and review of the literature.
    Meridor K, Levy Y.
    Autoimmun Rev; 2020 Jan; 19(1):102439. PubMed ID: 31734401
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. OROS-Methylphenidate-Induced Raynaud's Phenomenon: A Dose-Related Side Effect.
    Bayram Ö, Hergüner S.
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):521-2. PubMed ID: 26222712
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Raynaud phenomenon as adverse effect of ADHD treatment].
    Lakartidningen; 2015 Aug; 105(50):3662-3. PubMed ID: 19177933
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.
    Syed RH, Moore TL.
    J Clin Rheumatol; 2008 Feb; 14(1):30-3. PubMed ID: 18431096
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lisdexamfetamine and Secondary Raynaud's Phenomenon.
    Gnanavel S.
    Prim Care Companion CNS Disord; 2018 Sep 13; 20(5):. PubMed ID: 30256542
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.
    Pediatrics; 2003 Nov 13; 112(5):e404. PubMed ID: 14595084
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Attention deficit hyperactivity disorder, CNS stimulants and sport.
    Hickey G, Fricker P.
    Sports Med; 1999 Jan 13; 27(1):11-21. PubMed ID: 10028130
    [Abstract] [Full Text] [Related]

  • 19. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS.
    Drugs Today (Barc); 2013 Oct 13; 49(10):647-65. PubMed ID: 24191257
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.